NASDAQ: AVTX

Avalo Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for AVTX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Avalo Therapeutics, Inc. (NASDAQ: AVTX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 15:01 UTC.

What Avalo Therapeutics, Inc. does

Avita Bioventures is a clinical-stage biotechnology company focused on developing IL-1-based treatments for immune-mediated inflammatory diseases. The company's lead product candidate is abdakibart (AVTX-009), a humanized monoclonal antibody currently in a Phase 2 clinical trial called LOTUS for hidradenitis suppurativa, a chronic inflammatory skin disease. The LOTUS trial, which recently completed enrollment, is evaluating two dosing regimens of abdakibart against placebo in adults with moderate to severe hidradenitis suppurativa, with topline results expected in the second quarter of 2026.

Summarized from Avalo Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation	8-K 2026-06-23
Return on equity	-94.23%

Revenue, margins & earnings

Net income
Taxes & interest
Operating costs
Net loss year

Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-10-02

2026-10-02DirectorStock Option (Right to Buy)Award1,109$13.6K
2026-10-02DirectorStock Option (Right to Buy)Award1,352$16.6K
2026-10-02DirectorStock Option (Right to Buy)Award1,322$16.2K

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

FMR LLC5,100,216$94.25M+84.9%
BlackRock, Inc.4,365,553$80.68M+1234.7%
Deep Track Capital, LP3,610,000$66.71M+2396.5%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2026-06-12Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2022-02-18Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2021-12-06Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersPhilip Gutry'sEstimatedSEC 8-K →

Company news

View all →

Avalo Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com2026-09-03
Avalo Therapeutics Announces Pricing of $375 Million Public Offering
globenewswire.com2026-05-05
Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa
globenewswire.com2026-05-05POS

Questions this page answers

What does Avalo Therapeutics, Inc. do?

Avita Bioventures is a clinical-stage biotechnology company focused on developing IL-1-based treatments for immune-mediated inflammatory diseases.

When did AVTX last file with the SEC?

Avalo Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-23. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 15:01 UTC. This page is also available as JSON at /api/data?ticker=AVTX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for AVTX and 5,000+ tickers.

Create a free account — keep AVTX

For your agent

GET /api/data?ticker=AVTX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt